Retinopathy Of Prematurity | sciencenewsnet.in

Breaking News

Accelerated radiation treatment could reduce head and neck cancer patient burden in low- and middle-income countries

Initiative to Strengthen Response to Infectious Disease Outbreaks in the Mountain West

Chemistry Student Studies Sustainable Energy Solutions at National Lab

Wall Street Journal Ranks CSUF No. 7 ‘Best Value’ College in the U.S.

UC Irvine to host ‘conversations across the divide’ during its Year of Free Speech

Researchers Discover Promising Treatment to Combat Hospital Superbug

Canisius University’s Wehle School of Business Earns High Marks from US News

Rutgers Receives $4.2 Million to Develop Center for Alzheimer’s and Dementia Research in Asian and Pacific Americans

UC San Diego Health Physicians Top the List

Exploring Genetic Changes in Aggressive Pancreatic Cancer

03 Oct, 2023

Non-Invasive Approach Predicts Retinopathy of Prematurity Earlier

June 29, 2023 sarah JonasResearch Results

Research from Ann & Robert H. Lurie Children’s Hospital of Chicago promises to spare many premature infants from undergoing invasive eye exams to detect retinopathy of prematurity (ROP), the most common cause of preventable lifelong blindness in children in the U.S.

Very low-dose Avastin effective for preventing blindness in preterm infants

April 23, 2020 sarah JonasResearch Results

Babies born prematurely who require treatment to prevent blindness from retinopathy of prematurity (ROP) could be treated with a dose of Avastin (bevacizumab) that is a fraction of the dose commonly used for ROP currently. Results from the dose-finding study were published April 23 in JAMA Ophthalmology. The study was conducted by the Pediatric Eye Disease Investigator Group (PEDIG) and supported by the National Eye Institute (NEI), part of the National Institutes of Health.